200 evacuated after chemical incident
Nine people were taken to hospital and 200 evacuated following a chemical incident at a public pool in Melbourne's north.
Fire Rescue Victoria (FRV) were called to the Broadmeadows Leisure Centre about 6.15pm on Friday night after people reported the smell of gas inside the centre.
Firefighters found multiple people affected by the chemicals upon arrival.
A FRV spokesperson confirmed to NewsWire that nine people were taken to hospital for treatment following the incident.
About 200 people were evacuated from the leisure centre while FRV hazmat specialists ventilated the premises.
A positive reading for sodium hydrogen sulphate was found by the hazmat specialists.
The centre was confirmed to be safe to re-enter two hours later by FRV.
Sodium hydrogen sulphate, also known as sodium bisulphate, can be used to adjust pH levels in water.
NewsWire has contacted Hume City Council for comment.
More to come …
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
a day ago
- Forbes
New Study Finds Women And Young People Hit Hardest By Climate Anxiety
A young woman holds a cardboard 'No nature, no future'. (Photo by Alain Pitton/NurPhoto via Getty ... More Images) I never quite believed climate anxiety was real until about a year ago when I spoke to a couple of young people who shared that they were unsure whether they wanted to have children in the future. Their reasoning was simple and complex to shake off: who wants to bring a child into a world of droughts, floods, and other extreme weather events linked to climate change? So, when I read about the finding of the new study published in the Journal of Global Environmental Change that such anxiety particularly impacts women and young people, it stirred my curiosity. Whether one believes in climate anxiety or not, it's hard to deny that more and more young people are experiencing it. Climate anxiety responds to an uncertain future where climate change threatens long-term survival. Just a few days ago, thousands of citizens from Tuvalu—a small island nation in the Pacific facing the risk of drowning due to rising sea levels—applied for a climate-linked visa ballot to move to Australia, showcasing just how real the situation is. The reality of climate anxiety is strongly supported by academic research. The new study released this week by psychologists is not the first to report investigating the impact of climate-related anxiety. There have been many more in the past, covering many countries. For example, a survey of over 4,000 students in Germany earlier this month found that more than 40% experienced high or extreme levels of climate anxiety. Another study by Yale University found that about 64% of respondents in the US were worried about climate change. However, the new research stands out—it is the first meta-analysis, combining results from 94 studies involving 170,747 adults across 27 countries. It also underscores that women and young people are especially likely to experience climate anxiety. These studies on climate anxiety raise a key question: What are we doing about this? The growing evidence suggests the urgent need to consider the mental health aspects of climate adaptation alongside the other dimensions. They also highlight that the mental health impacts of climate change deserve to be integrated into climate and health planning more holistically. Why Addressing Climate Anxiety Is Essential to Climate Adaptation Climate adaptation isn't just about helping biodiversity and ecosystems adjust to rising temperatures, protecting jobs, housing, or migration from low-lying areas. It also means offering psychological support for people suffering from climate anxiety—whether caused by economic losses, displacement, or anxiety about the future. The American Psychological Association recommends building psychologists' capacity to help individuals cope with and adapt to climate change as a key part of its action plan for psychologists. This recommendation is critical as the number of physiologists dealing with patients who have expressed these concerns is not tiny anymore. One survey from Germany shows that 72% of psychotherapists reported having patients who raised concerns about climate change during treatment, as evidenced by a nationwide survey of 573 professionals. Breaking The Silos Between Climate And Health The intersection of climate and health—both physical and mental—is still underexplored. Understanding the climate-health nexus means examining how climate change affects health and how health systems can support climate action. This integrated understanding of climate and health calls for sustainability professionals to pay closer attention to health outcomes and for health professionals to respond to the growing pressures that climate change places on healthcare systems. The US National Academy of Medicine has begun advancing this conversation. It has started convening climate and health professionals to co-develop a roadmap for transformative action toward achieving health for all at net zero emissions. Where Do We Go From Here? It is not surprising that young people are at the forefront of climate anxiety—they are the ones who will face the long-term consequences of today's decisions. Here are two keyways forward: Managing climate action is not just about managing natural or economic resources. It's also about safeguarding people's well-being. With 1.8 billion young people under 25 in the world now, climate anxiety cannot be ignored in strategies to cope with a future of living with climate change.
Yahoo
a day ago
- Yahoo
What's gambling cost? Advocates slam political inaction
Australia risks losing a whole generation of kids to gambling, as criticisms are levelled at the government for failing to implement reforms from a landmark report two years on. The "You win some, you lose more" parliamentary inquiry into online gambling and its impacts, chaired by fierce gambling reform advocate the late Peta Murphy MP, delivered 31 recommendations in 2023. The unanimously supported proposals focused on reducing harm, protecting children and applying a long-overdue public health approach to gambling in this country. But two years to the day, gambling reform advocates, health bodies and church groups say the federal government have been silent. More than 80 per cent of Australians want a gambling advertisement ban, and parents are sick of turning on the TV only to find their 10-year-olds discussing the game in terms of odds, Alliance for Gambling Reform chief advocate Tim Costello said. "Smoking is legal, but kids shouldn't be seeing it. Same with gambling. People can gamble, but there's grooming of kids," Rev Costello told AAP. "We now have, with the two-year implementation (delay), a whole generation of kids who only think of NRL and AFL in terms of odds." Gambling harms lead to suicides, one-in-four 18-to-24-year-old young men are addicted, 600,000 underage Australians gambled last year, and domestic violence spikes threefold if there is gambling in a family, Rev Costello said. "This industry has been treated as having a normal social license when it's actually pushing very addictive products," he said. "We have literally given our kids over to sports betting companies as fodder for their profits." Vested interests, including the AFL and NRL, sports betting companies, and the commercial broadcasting networks, had stalled reforms, Rev Costello said. The nation's peak body for doctors, the Australian Medical Association, is demanding the government immediately action all 31 recommendations, accusing it of exposing millions of Australians to predatory betting companies. "Every day of delay means more Australians fall victim to an industry that profits from harm and despair," AMA President Danielle McMullen said. Wesley Mission chief executive Stu Cameron expressed deep disappointment in the government's failure to act on a bipartisan road map to tackle gambling harm. "Two years on, the silence from Canberra is deafening," Rev Cameron said. "While the government hesitates, lives are being torn apart." The three say the government must use their parliamentary mandate to make systematic reforms, including banning gambling ads, implementing a national regulator and treating gambling as a health issue. A spokesman for Communications Minister Anika Wells said she has had several meetings with harm reduction advocates, broadcasters and sporting codes. He said the government had delivered "some of the most significant gambling harm reduction measures in Australian history", pointing to mandatory ID verification and banning credit cards for online gambling and launching BetStop, the National Self-Exclusion Register. Australians top the list for the world's highest gambling losses, placing $244.3 billion in bets every year. National Gambling Helpline 1800 858 858 Lifeline 13 11 14 beyondblue 1300 22 4636 1800 RESPECT (1800 737 732) Men's Referral Service 1300 766 491
Yahoo
2 days ago
- Yahoo
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA
BRISBANE, Australia, June 25, 2025 /PRNewswire/ -- Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced Soft Tissue Sarcoma (STS). An Objective Response Rate (ORR) of 80% was achieved, based on the Best Observed Response (BOR) at any time during the study, indicating 8 out of 10 evaluable patients saw either complete ablation (100% reduction in volume) or partial ablation (≥30% reduction in volume) of treated tumours. 22 of the 27 (81%) injected tumours across all patients showed complete or partial ablation (14 showing complete ablation and 8 showing partial ablation). None of the 14 completely ablated tumours recurred at 6 months, indicating tigilanol tiglate may provide durable responses. QBiotics Group Limited (QBiotics) is pleased to announce final efficacy and safety data from the first of its two stage, Phase IIa clinical trial in patients with Soft Tissue Sarcoma (STS). STS is a rare type of cancer that generally forms as a painless lump (tumour) in any one of the soft tissues in the body. There were approximately 128,000 new cases of STS globally in 2023, with the incidence growing at 0.54% per year.[1] QBiotics' CEO and Managing Director, Stephen Doyle commented, "We are delighted with the outcomes from Stage 1 of our Phase IIa Soft Tissue Sarcoma trial. Tigilanol tiglate met both its primary and secondary endpoints and delivered patients an impressive 80% Objective Response Rate in injected tumours. Importantly, none of the 14 fully ablated (destroyed) tumours had recurred by the 6-month follow-up period, suggesting tigilanol tiglate may provide long-term benefit for patients. Given soft tissue sarcoma is a challenging cancer to treat, achieving this level of clinical activity is highly encouraging." "Our thanks to every trial patient, and also to the trial Investigators, Dr. Edmund Bartlett and his team at Memorial Sloan Kettering Cancer Center in New York. Given the positive results from Stage 1 of the trial – and compelling investigator reports that tigilanol tiglate may improve responses to systemic therapies in metastatic STS – we have moved ahead with the expansion arm of the study, announced late last year." Dr. Edmund Bartlett, Principal Trial Investigator at Memorial Sloan Kettering Cancer Center commented, "The clinical activity of tigilanol tiglate, which we observed in multiple types of soft tissue sarcoma, was encouraging. I look forward to expanding our experience with this treatment and determining how to integrate it into the care of patients with soft tissue sarcoma." ABOUT TRIAL QB46C-H07 QB46C-H07 (Clinical trial registration, NCT05755113) is a Phase IIa, open label, clinical trial evaluating the preliminary efficacy and safety of intratumoural tigilanol tiglate in patients with a range of advanced and/or metastatic STS. QB46C-H07 is being conducted in two stages: Stage 1 is a pilot trial in 10 patients. Stage 2 is an expansion trial. The results of Stage 1 are reported here. Eleven patients were administered tigilanol tiglate (0.5 mg tigilanol tiglate/cm3 tumour volume) to one or more of their tumours. Ten patients were included in the response evaluable population (where patients had a tumour assessment at both baseline and at 28 days post-treatment). The primary efficacy endpoint was Objective Response Rate (ORR) of injected tumours, compared to baseline. ORR was defined as the proportion of patients who achieved complete ablation (100% reduction in volume) or partial ablation (≥ 30% reduction in volume) of treated tumours and/or tumour segments following one or more treatments (up to 5 treatments) with tigilanol tiglate. Patients who achieved a ≥ 30% reduction in volume, irrespective of the number of treatments they received, were considered to have a response to tigilanol tiglate. Secondary endpoints include safety and tolerability assessments, and pharmacokinetics. Exploratory endpoints include local rate of recurrence at the injection site at 6 months post-initial injection, and assessment of tumour response in biopsy samples. Surgical specimens and blood samples were used to assess changes in tumour biomarkers. Efficacy and Safety Outcomes The ORR was 80% indicating 8 out of 10 evaluable patients achieved either complete or partial ablation of their treated tumours or tumour segments at any time during the study (Best Observed Response, BOR). There was a median of 2 treatments of tigilanol tiglate per patient (range 1 to 5). At the tumour level, 22 of 27 (81%) treated tumours showed either complete or partial responses as the Best Observed Response. 14 out of 27 tumours (52%) demonstrated complete ablation, while 8 out of 27 tumours (30%) demonstrated partial ablation. These results indicate a high level of efficacy for tigilanol tiglate in achieving complete or partial tumour ablation. Importantly, none of the complete responses (n=14) recurred by 6 months, the follow-up period, indicating tigilanol tiglate may provide durable responses. All 11 tigilanol tiglate treated patients were included in the safety evaluation. Tigilanol tiglate was well tolerated. Most of the Adverse Events (AEs) were expected and related to the local action of the drug (e.g. local pain, swelling, necrosis). Conclusions Overall, the study results indicate tigilanol tiglate is well tolerated and shows promising efficacy in reducing tumour volume, with 80% of patients experiencing complete (100%) ablation or partial (≥30%) ablation of their tumours. The absence of tumour recurrence in cases achieving a complete response further underscores tigilanol tiglate's potential as an effective treatment option for soft tissue sarcomas and possibly other solid tumours. The promising tumour responses reported here, together with observations that three patients exhibited better than expected responses to subsequent systemic therapy (as presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting in November 2024),[2] have supported the progression of the QB46C-H07 study to Stage 2. The trial expansion (referred to as Stage 2) aims to further investigate the clinical utility and therapeutic potential of tigilanol tiglate in patients with STS. Stage 2 of the trial is opening shortly at Memorial Sloan Kettering Cancer Center in New York, USA. References GlobalData®, American Cancer Society, Cancer Australia, Cancer Research UK, Canadian Cancer Society. Bartlett et al, 2024. The Connective Tissue Oncology Society (CTOS) Annual Meeting, Nov 13-16, 2024, San Diego, USA. NOTES FOR EDITORS ABOUT QBIOTICS QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program. QBiotics' lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024. A veterinary formulation of tigilanol tiglate (STELFONTA®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA®. Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment. For more, head to: or LinkedIn. View original content to download multimedia: SOURCE QBiotics Group Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
